diabetestalk.net

Glimepiride Metformin Fixed Dose Combination

Triple Fixed Drug Combinations In Type 2 Diabetes John M, Gopinath D, Kalra S - Indian J Endocr Metab

Triple Fixed Drug Combinations In Type 2 Diabetes John M, Gopinath D, Kalra S - Indian J Endocr Metab

John M, Gopinath D, Kalra S. Triple fixed drug combinations in type 2 diabetes. Indian J Endocr Metab 2015;19:311-3 John M, Gopinath D, Kalra S. Triple fixed drug combinations in type 2 diabetes. Indian J Endocr Metab [serial online] 2015 [cited2018 Jun 5];19:311-3. Available from: Type 2 diabetes is characterized by progressive beta-cell failure that results in sequential adding of different oral and injectable medications to achieve optimal glycemic control. [1] , [2] This necessitates administration of multiple tablets or pills to achieve good glycemic control as the disease progresses. [2] In addition, subjects with type 2 diabetes may have other co-morbidities such as dyslipidemia, hypertension and cardiovascular disease, which further increase the burden of medications. Polypharmacy with increased pill burden and dosing frequency is identified as one of the factors responsible for poor adherence to oral hypoglycemic therapy. [3] Even in countries with high access to healthcare, only 39% of patients reported good medication adherence. [4] In a study of 2741 patients on oral antidiabetic drug (OAD), there was an inverse relationship between OAD adherence and HbA 1 c; controlling for baseline HbA1c and therapy regimen, each 10% increase in oral diabetes medication adherence was associated with a 0.1% HbA1c decrease (P = 0.0004), suggesting that adherent patients are more likely to achieve glycemic control than the nonadherent ones. [5] One method to improve drug adherence is to use fixed drug combinations (FDC). [6] United States Food and Drugs Administration (USFDA) defines FDC as "two or more drugs may be combined in a single dosage form when each component makes a contribution to the claimed effects and the dosage of each component (amount, frequency, duration) i Continue reading >>

Efficacy Of Glimepiride/metformin Fixed-dose Combination Vs Metformin Uptitration In Type 2 Diabetic Patients Inadequately Controlled On Low-dose Metformin Monotherapy: A Randomized, Open Label, Parallel Group, Multicenter Study In Korea.

Efficacy Of Glimepiride/metformin Fixed-dose Combination Vs Metformin Uptitration In Type 2 Diabetic Patients Inadequately Controlled On Low-dose Metformin Monotherapy: A Randomized, Open Label, Parallel Group, Multicenter Study In Korea.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine Seoul, Korea. To compare the efficacy and safety of early combination therapy with glimepiride/metformin to metformin uptitration in reducing glycated hemoglobin (HbA1c) levels in Korean type2 diabetic patients inadequately controlled on low-dose metformin monotherapy. In a randomized, open label, parallel group, multicenter study, 209 Korean type2 diabetic patients (HbA1c 7.0-10.0%, on metformin 500-1,000mg/day) received glimepiride/metformin fixed-dose combination (G/M FDC) or metformin uptitration treatment (Met UP). The primary end-point was the change in HbA1c from baseline to week24. G/M FDC therapy provided significantly greater adjusted mean decreases vs Met UP therapy in HbA1c (-1.2 vs -0.8%, P<0.0001), and fasting plasma glucose (-35.7 vs -18.6mg/dL, P<0.0001). A significantly greater proportion of patients with G/M FDC therapy achieved HbA1c<7% (74.7 vs 46.6%, P<0.0001) at the end of the study. More patients experienced hypoglycemia with G/M FDC therapy compared with Met UP therapy (41 vs 5.6%, P<0.0001), but there was no serious hypoglycemia in any group. A modest increase in mean bodyweight occurred in the patients who were treated with G/M FDC therapy (1.0kg), whereas a slight decrease was observed in the patients who were treated with Met UP therapy (-0.7kg). The present study showed that glimepiride/metformin fixed-dose combination therapy was more effective in glycemic control than metformin uptitration, and was well tolerated in type2 diabetic patients inadequately controlled by low-dose metformin monotherapy in Korea. This trial was registered with ClinicalTrial.gov (no. NCT00612144 ). Glimepiride/metformin combination; Korea; Type 2 diabet Continue reading >>

Evaluation Of Fixed Dose Combination Of Glimepiride And Metformin In Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin

Evaluation Of Fixed Dose Combination Of Glimepiride And Metformin In Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin

You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT01457911 Information provided by (Responsible Party): To evaluate the efficacy of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone in terms of glycemic control as reflected by HbA1c during a 20-week treatment period in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. To evaluate the percentage of patients reaching HbA1c < 7% or HbA1c 6.5% of fixed dose combination of 1 mg glimepiride and 250 mg metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone at week 20. To evaluate the effect on Fasting Plasma Glucose of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone at week 20. To assess the safety and tolerability of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg). Fasting plasma glucose > 250 mg/dL (> 13.9 mmol/L) Patients who have not been on stable daily dose of at least 1500 mg metformin within 3 months prior to screening Patients currently receiving or who have received anti-diabetic drugs other than metformin within 3 months prior to screening The above information is not intended to contain all considerations relevant to a patient's potential partic Continue reading >>

Ebscohost | 96426544 | Bioequivalence Comparison Of Two Formulations Of Fixed-dose Combination Glimepiride/metformin (2/500 Mg)tablets In Healthy Volunteers.

Ebscohost | 96426544 | Bioequivalence Comparison Of Two Formulations Of Fixed-dose Combination Glimepiride/metformin (2/500 Mg)tablets In Healthy Volunteers.

Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers. Source: Iranian Journal of Pharmaceutical Research . Spring2014, Vol. 13 Issue 2, p365-371. 7p. Author(s): Sang-hoon Jung; Jung-woo Chae; Byung-jeong Song; Kwang-il Kwon Abstract: Glimepiride/metformin (2/500 mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin (2/500 mg) fixed-dose combination (FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities to allow the marketing of the test formulation. We evaluated the comparative bioavailability and tolerability of the test and reference formulations in healthy male adult volunteers.This single-dose, randomized, double-blind, two-way crossover trial was conducted at Bestian Medical Center in Bucheon, Korea. In total, 40 male Korean volunteers were enrolled. The subjects were randomized to receive an FDC tablet containing the glimepiride/metformin (2/500 mg) test or reference formulation, and pharmacokinetic(PK) parameters were measured. After a 1-week washout period, the other formulation was administered and the PK parameters were measured again. The Cmax and AUCt were determined from blood samples obtained at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 h after drug administration. Bioequivalence was considered established if the 90% CIs of the geometric mean ratios(GMRs) of the test-to-reference formulations for Cmax and AUCt were within the predetermined regulatory range of 80-125%. Intotal, 40 healthy male subjects were enrolled and completed the study (mean [SD] age, 23.2[2.26]years[range, 19-30years];weight, Continue reading >>

Evaluation Of Fixed Dose Combination Of Glimepiride And Metformin In Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin

Evaluation Of Fixed Dose Combination Of Glimepiride And Metformin In Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin

Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin glimepiride and metformin hydrochloride combination (hoe490), glimepiride (hoe490) - To evaluate the efficacy of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone in terms of glycemic control as reflected by HbA1c during a 20-week treatment period in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. - To evaluate the percentage of patients reaching HbA1c < 7% or HbA1c 6.5% of fixed dose combination of 1 mg glimepiride and 250 mg metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone at week 20. - To evaluate the effect on Fasting Plasma Glucose of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone at week 20. - To assess the safety and tolerability of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg). AMARYL M (Glimepiride and Metformin hydrochloride combination) AMARYL M at a dosage regimen from 1 tablet to 6 tablets, once during a meal or twice during a meal glimepiride and metformin hydrochloride combination (hoe490) Pharmaceutical form:tablet Route of administration: oral AMARYL at a dosage regimen from 1 mg to 6 mg, once during a meal or twice during a meal Pharmaceutical form:tablet Route of administration: oral time frame:20 weeks, from baseline to week 20 Percentage of patients reaching HbA1c < 7% or HbA1c 6.5%, respectively Absolute change in Fasting Plasma Glucose time frame:20 weeks, from baseline to week 20 Number of patients reporting adverse events time frame:20 weeks, from baseline to week 20 Number of patient Continue reading >>

Efficacy Of Glimepiride/metformin Fixed-dose Combination Vs Metformin Uptitration In Type 2 Diabetic Patients Inadequately Controlled On Low-dose Metformin Monotherapy: A Randomized, Open Label, Parallel Group, Multicenter Study In Korea

Efficacy Of Glimepiride/metformin Fixed-dose Combination Vs Metformin Uptitration In Type 2 Diabetic Patients Inadequately Controlled On Low-dose Metformin Monotherapy: A Randomized, Open Label, Parallel Group, Multicenter Study In Korea

N2 - Aims/Introduction: To compare the efficacy and safety of early combination therapy with glimepiride/metformin to metformin uptitration in reducing glycated hemoglobin (HbA1c) levels in Korean type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy. Materials and Methods: In a randomized, open label, parallel group, multicenter study, 209 Korean type 2 diabetic patients (HbA1c 7.0-10.0%, on metformin 500-1,000 mg/day) received glimepiride/metformin fixed-dose combination (G/M FDC) or metformin uptitration treatment (Met UP). The primary end-point was the change in HbA1c from baseline to week 24. Results: G/M FDC therapy provided significantly greater adjusted mean decreases vs Met UP therapy in HbA1c (-1.2 vs -0.8%, P < 0.0001), and fasting plasma glucose (-35.7 vs -18.6 mg/dL, P < 0.0001). A significantly greater proportion of patients with G/M FDC therapy achieved HbA1c < 7% (74.7 vs 46.6%, P < 0.0001) at the end of the study. More patients experienced hypoglycemia with G/M FDC therapy compared with Met UP therapy (41 vs 5.6%, P < 0.0001), but there was no serious hypoglycemia in any group. A modest increase in mean bodyweight occurred in the patients who were treated with G/M FDC therapy (1.0 kg), whereas a slight decrease was observed in the patients who were treated with Met UP therapy (-0.7 kg). Conclusion: The present study showed that glimepiride/metformin fixed-dose combination therapy was more effective in glycemic control than metformin uptitration, and was well tolerated in type 2 diabetic patients inadequately controlled by low-dose metformin monotherapy in Korea. This trial was registered with ClinicalTrial.gov (no. NCT00612144). AB - Aims/Introduction: To compare the efficacy and safety of early combination therapy with gli Continue reading >>

Efficacy And Safety Of The Fixed Dose Combination Of Glimepiride+metformin In Type 2 Diabetic Patients Inadequately Controlled (legend)

Efficacy And Safety Of The Fixed Dose Combination Of Glimepiride+metformin In Type 2 Diabetic Patients Inadequately Controlled (legend)

Percentage of patients with HbA1c < 7% [TimeFrame:at week 24] Percentage of patients with HbA1c < 6.5% [TimeFrame:at week 24] Change in Fasting Plasma Glucose (FPG) [TimeFrame:from baseline to week 24] Number of patients with adverse events [TimeFrame:over the 24-week treatment period] Hypoglycemia [TimeFrame:over the 24-week treatment period] Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Patients with type 2 diabetes mellitus inadequately controlled despite a treatment with sulfonylurea (SU) alone or metformin alone or a free combination of SU and metformin prior to the study entry. Signed informed consent, obtained prior any study procedure Treatment with a stable dose of maximally tolerated SU alone or metformin alone or the free combination of SU and metformin for less than 12 weeks prior to the screening visit. Patients who received any anti-diabetic drug other than SU or metformin within 12 weeks prior to the screening visit. Diabetes other than type 2 diabetes (e.g. type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations Continue reading >>

Comparison Of The Efficacy And Safety Of Glimepiride/metformin Fixed Combination Versus Free Combination In Patients With Type 2 Diabetes: Multicenter, Randomized, Controlled Trial

Comparison Of The Efficacy And Safety Of Glimepiride/metformin Fixed Combination Versus Free Combination In Patients With Type 2 Diabetes: Multicenter, Randomized, Controlled Trial

Your browser does not support the NLM PubReader view. Go to this page to see a list of supporting browsers. Comparison of the Efficacy and Safety of Glimepiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial J Korean Diabetes Assoc. 2006 Nov;30(6):466-475. J Korean Diabetes Assoc. 2006 Nov;30(6):466-475. Korean. Published online November 30, 2006. Copyright 2006 Korean Diabetes Association Comparison of the Efficacy and Safety of Glimepiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial Seung-Hwan Lee,In-Kyu Lee,1Sei-Hyun Baik,2Dong-Seop Choi,3Kyong-Soo Park,4Ki-Ho Song,5Kwan-Woo Lee,6Bong-Soo Cha,7Chul-Woo Ahn,8Hyoung-Woo Lee,9Choon-Hee Chung,10Moon-Suk Nam,11Hong-Sun Baek,12Yong-Ki Kim,13Hyo-Young Rhim,14 and Ho-Young Son Kangnam St. Mary's hospital, The Catholic University of Korea, Korea. 1Keimyung University Medical Center, Korea. 4Seoul National University Hospital, Korea. 5St. Vincent Hospital, The Catholic University of Korea, Korea. 7Severance Hospital, Yonsei University, Korea. 8Yongdong Severance Hospital, Yonsei University, Korea. 9Yeongnam University Medical Center, Korea. 12Chonbuk National University Hospital, Korea. 13Pusan National Universtiy Hospital, Korea. 14Handok Pharmaceuticals Co., LTD., Korea. Received May 29, 2006; Accepted November 20, 2006. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:14141431. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes Continue reading >>

Comparison Of The Efficacy And Safety Of Glimepiride/metformin Fixed Combination Versus Free Combination In Patients With Type 2 Diabetes: Multicenter, Randomized, Controlled Trial

Comparison Of The Efficacy And Safety Of Glimepiride/metformin Fixed Combination Versus Free Combination In Patients With Type 2 Diabetes: Multicenter, Randomized, Controlled Trial

Your browser does not support the NLM PubReader view. Go to this page to see a list of supporting browsers. Comparison of the Efficacy and Safety of Glimepiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial J Korean Diabetes Assoc. 2006 Nov;30(6):466-475. J Korean Diabetes Assoc. 2006 Nov;30(6):466-475. Korean. Published online Nov 30, 2006. Copyright 2006 Korean Diabetes Association Comparison of the Efficacy and Safety of Glimepiride/Metformin Fixed Combination Versus Free Combination in Patients with Type 2 Diabetes: Multicenter, Randomized, Controlled Trial Seung-Hwan Lee,In-Kyu Lee,1Sei-Hyun Baik,2Dong-Seop Choi,3Kyong-Soo Park,4Ki-Ho Song,5Kwan-Woo Lee,6Bong-Soo Cha,7Chul-Woo Ahn,8Hyoung-Woo Lee,9Choon-Hee Chung,10Moon-Suk Nam,11Hong-Sun Baek,12Yong-Ki Kim,13Hyo-Young Rhim,14 and Ho-Young Son Kangnam St. Mary's hospital, The Catholic University of Korea, Korea. 1Keimyung University Medical Center, Korea. 4Seoul National University Hospital, Korea. 5St. Vincent Hospital, The Catholic University of Korea, Korea. 7Severance Hospital, Yonsei University, Korea. 8Yongdong Severance Hospital, Yonsei University, Korea. 9Yeongnam University Medical Center, Korea. 12Chonbuk National University Hospital, Korea. 13Pusan National Universtiy Hospital, Korea. 14Handok Pharmaceuticals Co., LTD., Korea. Received May 29, 2006; Accepted November 20, 2006. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:14141431. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mell Continue reading >>

Bioequivalence Comparison Of Two Formulations Of Fixed-dose Combination Glimepiride/metformin (2/500 Mg)tablets In Healthy Volunteers

Bioequivalence Comparison Of Two Formulations Of Fixed-dose Combination Glimepiride/metformin (2/500 Mg)tablets In Healthy Volunteers

Jung, S., Chae, J., Song, B., Kwon, K. (2014). Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers. Iranian Journal of Pharmaceutical Research, 13(2), 365-371. Sang-hoon Jung; Jung-woo Chae; Byung-jeong Song; Kwangil Kwon. "Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers". Iranian Journal of Pharmaceutical Research, 13, 2, 2014, 365-371. Jung, S., Chae, J., Song, B., Kwon, K. (2014). 'Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers', Iranian Journal of Pharmaceutical Research, 13(2), pp. 365-371. Jung, S., Chae, J., Song, B., Kwon, K. Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers. Iranian Journal of Pharmaceutical Research, 2014; 13(2): 365-371. Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers College of Pharmacy, Chungnam National University Glimepiride/metformin(2/500mg) is an oral antihyperglycemic agent for the treatment of type 2 diabetes. A generic glimepiride/metformin(2/500mg) fixed-dose combination(FDC) tablet was developed recently. This study was designed to collect data for submission to Korean regulatory authorities to allow the marketing of the test formulation. We evaluated the comparative bioavailability and tolerability of the test and reference formulations in healthy male adult volunteers. This single-dose, randomized, double-blind, two-way crossover trial was conducted at Bestian Medical Center in Bucheon, Korea. In total, 40male Continue reading >>

A Fixed-dose Combination Of Pioglitazone And Metformin:a Promising Alternative In Metabolic Control

A Fixed-dose Combination Of Pioglitazone And Metformin:a Promising Alternative In Metabolic Control

Get access/doi/pdf/10.1185/030079906X121002?needAccess=true Background: When type 2 diabetes is managed with glucose-lowering monotherapy, glycemic control ultimately deteriorates due to the inability of the -cell to overcome insulin resistance. Combining drugs with different complementary mechanisms of action improves long-term glycemic control and may lower the risk of vascular complications. A fixed-dose combination of pioglitazone (a thiazolidinedione) and metformin has been approved for use in the US (Actoplus met ) and in Europe (Competact ). Scope: This review (based upon MEDLINE and EMBASE searches from January 1990 to April 2006) discusses the potential benefits of co-formulating metformin and pioglitazone with respect to compliance and targeting glycemia, as well as other metabolic parameters. Findings: Pioglitazone increases insulin sensitivity, while metformin reduces hepatic gluconeogenesis and improves peripheral glucose uptake. Both agents reduce hyperglycemia and hyperinsulinemia, and appear to protect cell function. Their similar pharmacokinetic time profiles have facilitated a co-formulation bioequivalent to their separate administration. In randomized studies, pioglitazone and metformin administered separately provided significantly better glycemic control than metformin monotherapy or metformin plus gliclazide. Pioglitazone and metformin have complimentary benefits on diabetic dyslipidemia; pioglitazone primarily improves high-density lipoprotein cholesterol and triglyceride levels (to a greater extent than rosiglitazone does), while metformin mainly improves total cholesterol. Pioglitazone and metformin also modulate other atherosclerosis biomarkers, including inflammatory mediators, coagulation thrombosis components, and carotid intima media thick Continue reading >>

Fixed-dose Combinations In Type 2 Diabetes Role Of The Canagliflozin Metformin Combination

Fixed-dose Combinations In Type 2 Diabetes Role Of The Canagliflozin Metformin Combination

Editor who approved publication: Professor Ming-Hui Zou Joshua W Fleming, Laurie W Fleming, Courtney S Davis Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, Jackson, MS, USA Abstract: Canagliflozinmetformin is one of the newest combination therapies available for the treatment of type 2 diabetes mellitus (T2DM). Canagliflozin is an inhibitor of the sodiumglucose co-transporter 2 which causes an increase in the urinary excretion of glucose. In the present article, we review the safety and efficacy of canagliflozin and metformin from data obtained from Phase III metformin add-on therapy clinical trials as there are no studies to date that specifically evaluate the combination of metformin and canagliflozin. Trials included in this review were dual-therapy trials of subjects who were already taking background metformin and were assigned to receive canagliflozin, glimepiride, or sitagliptin. The addition of canagliflozin to metformin resulted in a decrease in HbA1c of 0.73%0.93%. Canagliflozin 100 mg was considered to be non-inferior to glimepiride and sitagliptin 100 mg with the canagliflozin 300 mg dose being statistically superior to sitagliptin and glimepiride. Other advantages of the use of canagliflozin are reduction in weight (3.34.0 kg) and systolic blood pressure (3.34.7 mmHg). The primary disadvantages are potential genital mycotic infections, hypotension, and gastrointestinal side effects from metformin. All things considered, this combination appears to be safe and effective in clinical trials and represents a promising option for the treatment of T2DM. Keywords: type 2 diabetes, fixed-dose combination (FDC), canagliflozin metformin This work is published and licensed by Dove Medical Press Limited. The full terms of this licen Continue reading >>

Effects Of Pioglitazone In Combination With Metformin Or A Sulfonylurea Compared To A Fixed-dose Combination Of Metformin And Glibenclamide In Patients With Type 2 Diabetes

Effects Of Pioglitazone In Combination With Metformin Or A Sulfonylurea Compared To A Fixed-dose Combination Of Metformin And Glibenclamide In Patients With Type 2 Diabetes

Diabetes Technology & Therapeutics Vol. 9, No. 4 Effects of Pioglitazone in Combination with Metformin or a Sulfonylurea Compared to a Fixed-Dose Combination of Metformin and Glibenclamide in Patients with Type 2 Diabetes Background: This study was designed to compare the effectiveness of co-administration of pioglitazone with metformin or a sulfonylurea (SU), with a fixed-dose combination of metformin and glibenclamide on glycemic control and -cell function in patients with type 2 diabetes. Methods: Patients (n = 250) treated with metformin (3 g/day) or an SU as monotherapy for >3 months and with glycosylated hemoglobin (HbA1c) between 7.5% and 11% inclusive were randomized to receive either pioglitazone (1530 mg/day) as add-on therapy to metformin or an SU or a fixed-dose combination of metformin (400 mg) and glibenclamide (2.5 mg) (up to three tablets per day) for 6 months. HbA1c and fasting plasma glucose (FPG) were measured at baseline and 2, 4, and 6 months. C-peptide levels were measured at baseline and 6 months, and post-challenge glucose and insulin responses were measured. Results: After 6 months, pioglitazone-based and fixed-dose metformin + glibenclamide resulted in similar reductions in HbA1c (1.11% vs. 1.29%, respectively; P = 0.192) and FPG (2.13 vs. 1.81 mmol/L, respectively; P = 0.370). Patients treated with pioglitazone for 6 months had significantly reduced C-peptide levels compared with baseline (0.09 nmol/L, P = 0.001), while patients receiving fixed-dose metformin + glibenclamide combination had slightly increased C-peptide levels (+0.04 nmol/L, P = 0.08). Pioglitazone treatment also improved post-challenge insulin responses. Conclusions: Co-administration of pioglitazone with metformin or an SU is an effective alternative to fixed-dose metformin Continue reading >>

Evaluation Of Fixed Dose Combination Of Glimepiride And Metformin In Patients With Type 2 Diabetes. Results Of Russian Observational Study

Evaluation Of Fixed Dose Combination Of Glimepiride And Metformin In Patients With Type 2 Diabetes. Results Of Russian Observational Study

Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study Authors: Zaytseva N.V., Jarek-Martynova I.R. To investigate the efficacy and safety of combined glimepiride and metformin therapy in patients with type 2 diabetes mellitus (T2DM). A multi-centre, open-label, prospective, observational study was conducted. A total of 1200 patients with T2DM inadequately controlled with metformin, glimepiride or combination of metformin + glimepiride were enrolled. Change in serum glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial blood glucose (PPG) levels; weight; waist circumference and hypoglycemic episodes were evaluated. Baseline HbA1c levels (8.24% ? 0.42%) were significantly reduced after 12 weeks of treatment (7.48% ? 0.48%) and at the end of the study. (6.88% ? 0.56%). Target HbA1c levels (?7%) were achieved in 65.1% of patients at the final visit at 24 weeks. FPG and PPG levels decreased by 1.45 ? 1.14 mmol/l and 2.17 ? 1.27 mmol/l respectively (p < 0.001). No severe hypoglycemic events were reported. Body mass index reduced by 0.85 ? 1.28 kg/m2 (p < 0.001). Combined glimepiride and metformin therapy significantly improved long-term glycemic control in patients with T2DM during the period of 24 weeks. without additional risk of hypoglycemic events or weight gain. C 2 (2) , . 2 , . , 2 - . 2 , [1]. , , , , , [2]. 2 ( ) - . 2 , , - . 2 . () 2015 . 2 [3]. 7- [4]. 2015 . ADA/EASD (American Diabetes Association/ European Association for the Study of Diabetes), 2 [5]. , , , (HbA1c) (). , , 2: , . 2 , . . , 2 , 2. -4, -1. , 6 HbA1c 0,5%, . . (HbA1c), 2, , , . . (IDF International Diabetes Federation, 2012) [6], ADA (2014) [7], (2011) [3], (ADVANCE Action in Diabetes and V Continue reading >>

Efficacy Of Glimepiride/metformin Fixed-dose Combination Vs Metformin Uptitration In Type 2 Diabetic Patients Inadequately Controlled On Low-dose Metformin Monotherapy: A Randomized, Open Label, Parallel Group, Multicenter Study In Korea

Efficacy Of Glimepiride/metformin Fixed-dose Combination Vs Metformin Uptitration In Type 2 Diabetic Patients Inadequately Controlled On Low-dose Metformin Monotherapy: A Randomized, Open Label, Parallel Group, Multicenter Study In Korea

Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Department of Internal Medicine, Hallym University College of Medicine, Internal Medicine, Yonsei University College of Medicine, Department of Internal Medicine, Konkuk University School of Medicine, Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Department of Endocrinology and Metabolism, Chonbuk National University Hospital, Jeonju, Department of Internal Medicine, Dongguk University College of Medicine, Goyang, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Paik Institute for Clinical Research, Department of Internal Medicine, College of Medicine, Inje University, Busan, and Department of Internal Medicine, Seoul National University Aims/Introduction:To compare the efficacy and safety of early combination therapy with glimepiride/metformin to metformin uptitration in reducing glycated hemoglobin (HbA1c) levels in Korean type 2 diabetic patients inadequately controlled on low-dose Materials and Methods:In a randomized, open label, parallel group, multicenter study, 209 Korean type 2 diabetic patients (HbA1c 7.010.0%, on metformin 500 1,000 mg/day) received glimepiride/metformin fixed-dose combination (G/M FDC) or met- formin uptitration treatment (Met UP). The primary end-point was the change in HbA1c Results:G/M FDC therapy provided significantly greater adjusted mean decreases vs Met UP therapy in HbA1c (-1.2 vs -0.8%, P<0.0001), and fasting plasma glucose (-35.7 vs -18.6 mg/dL, P<0.0001). A significantly greater proportion of patients with G/M FDC therapy achieved HbA1c <7% (74.7 vs 46.6%, P<0.0001) at the end of the study. More patients experienced hypoglycemia with G/M FDC Continue reading >>

More in diabetes